These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
105 related articles for article (PubMed ID: 2906066)
1. Administration of butaperazine and plasma methionine-enkephalin levels in schizophrenic and affective disorder patients with tardive dyskinesia. Mosnaim AD; Wolf ME J Clin Psychopharmacol; 1988 Aug; 8(4 Suppl):27S-30S. PubMed ID: 2906066 [TBL] [Abstract][Full Text] [Related]
2. Pyridoxal plasma level in schizophrenic and schizoaffective patients with and without tardive dyskinesia. Miodownik C; Meoded A; Libov I; Bersudsky Y; Sela BA; Lerner V Clin Neuropharmacol; 2008; 31(4):197-203. PubMed ID: 18670243 [TBL] [Abstract][Full Text] [Related]
3. High plasma clozapine levels in tardive dyskinesia. Pollack S; Lieberman J; Kleiner D; Szymanski S; Kane J; Borenstein M; Cooper T Psychopharmacol Bull; 1993; 29(2):257-62. PubMed ID: 8290674 [TBL] [Abstract][Full Text] [Related]
11. Withdrawal-emergent dyskinesia in patients with schizophrenia during antipsychotic discontinuation. Schultz SK; Miller DD; Arndt S; Ziebell S; Gupta S; Andreasen NC Biol Psychiatry; 1995 Dec; 38(11):713-9. PubMed ID: 8580223 [TBL] [Abstract][Full Text] [Related]
12. Tardive dyskinesia: relationship with a primary affective disorder. Rosenbaum AH; Niven RG; Hanson NP; Swanson DW Dis Nerv Syst; 1977 Jun; 38(6):423-7. PubMed ID: 16734 [TBL] [Abstract][Full Text] [Related]
13. Schizoaffective disorder: a form of schizophrenia or affective disorder? Evans JD; Heaton RK; Paulsen JS; McAdams LA; Heaton SC; Jeste DV J Clin Psychiatry; 1999 Dec; 60(12):874-82. PubMed ID: 10665641 [TBL] [Abstract][Full Text] [Related]
14. CYP2D6 polymorphism and tardive dyskinesia in schizophrenic patients. Lohmann PL; Bagli M; Krauss H; Müller DJ; Schulze TG; Fangerau H; Ludwig M; Barkow K; Held T; Heun R; Maier W; Rietschel M; Rao ML Pharmacopsychiatry; 2003; 36(2):73-8. PubMed ID: 12734765 [TBL] [Abstract][Full Text] [Related]
15. Clinical effectiveness of the Kampo medicine kamishoyosan for adjunctive treatment of tardive dyskinesia in patients with schizophrenia: a 16-week open trial. Lee JG; Shin BS; Lee YC; Park SW; Kim YH Psychiatry Clin Neurosci; 2007 Oct; 61(5):509-14. PubMed ID: 17875029 [TBL] [Abstract][Full Text] [Related]
16. Prolactin response in tardive dyskinesia. Wolf ME; Bowie L; Keener S; Mosnaim AD Biol Psychiatry; 1982 Apr; 17(4):485-90. PubMed ID: 7082714 [No Abstract] [Full Text] [Related]
17. Substance abuse as a risk factor for tardive dyskinesia: a retrospective analysis of 1,027 patients. Bailey LG; Maxwell S; Brandabur MM Psychopharmacol Bull; 1997; 33(1):177-81. PubMed ID: 9133772 [TBL] [Abstract][Full Text] [Related]
18. Psychopathological and cognitive correlates of tardive dyskinesia in schizophrenia and other disorders treated with neuroleptic drugs. Waddington JL Adv Neurol; 1995; 65():211-29. PubMed ID: 7872142 [No Abstract] [Full Text] [Related]
19. Factors related to the severity of tardive dyskinesia. Wade JB; Hart RP; Dougherty LM Brain Cogn; 1993 Sep; 23(1):71-80. PubMed ID: 8105823 [TBL] [Abstract][Full Text] [Related]
20. Haplotype analysis of endothelial nitric oxide synthase (NOS3) genetic variants and tardive dyskinesia in patients with schizophrenia. Liou YJ; Lai IC; Lin MW; Bai YM; Lin CC; Liao DL; Chen JY; Lin CY; Wang YC Pharmacogenet Genomics; 2006 Mar; 16(3):151-7. PubMed ID: 16495774 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]